RxDoctor Payments Data

Abby Newman, NP

Acute Care · Alexander City, ALNPI 1922644178

Payments from drug & device makers

$1,253in general payments, 2019–2025

Across 70 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$231
  • Amgen$212
  • Merck$211
  • Bayer$99
  • Boehringer Ingelheim$94
  • AstraZeneca$63
  • plus $341 from 11 others

What the payments were for

  • Food & beverage$1,23999%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,253 in reported general payments places this provider in the 70th percentile of 711 acute care providers in Alabama.

See all acute care providers in Alabama

Medicare billing

Part B allowed, 2024
$29,920
Medicare patients
59
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$23,215
FarxigaDapagliflozin Propanediol18$19,296
EntrestoSacubitril/Valsartan17$17,032
Repatha SureclickEvolocumab26$14,114
JardianceEmpagliflozin18$10,524
Ezetimibe33$1,447
Atorvastatin Calcium62$1,095
ClopidogrelClopidogrel Bisulfate29$447
Metoprolol Succinate30$400
Amiodarone Hcl23$396
Losartan Potassium17$211
Rosuvastatin Calcium20$199
Carvedilol16$135
Amlodipine Besylate13$113
Spironolactone11$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$23,21529 claims
AstraZenecaFarxiga$63$19,29618 claims
NovartisEntresto$13$17,03217 claims
Boehringer IngelheimJardiance$94$10,52418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 711 acute care providers in Alabama.

Other acute care in Alexander City

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →